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Background: SET and MYND domain-containing protein 2 (SMYD2) is a lysine methyltransferase for histone H3, p53 and Rb and
inhibits their transactivation activities. In this study, we tested whether SMYD2 (1q42) acts as a cancer-promoting factor by being
overexpressed in gastric cancer.
Methods: We analysed 7 gastric cancer cell lines and 147 primary tumor samples of gastric cancer, which were curatively resected
in our hospital.
Results: SET and MYND domain-containing protein 2 was detected in these cell lines (five out of seven cell lines; 71.4%) and
primary tumor samples (fifty-six out of one hundred and forty-seven cases; 38.1%). Knockdown of SMYD2 using specific small
interfering RNA inhibited proliferation, migration and invasion of SMYD2-overexpressing cells in a TP53 mutation-independent
manner. Overexpression of SMYD2 protein correlated with larger tumor size, more aggressive lymphatic invasion, deeper tumor
invasion and higher rates of lymph node metastasis and recurrence. Patients with SMYD2-overexpressing tumours had a worse
overall rate of survival than those with non-expressing tumours (P¼ 0.0073, log-rank test) in an intensity and proportion score-
dependent manner. Moreover, multivariate analysis demonstrated that SMYD2 was independently associated with worse outcome
(P¼ 0.0021, hazard ratio 4.25 (1.69–10.7)).
Conclusions: These findings suggest that SMYD2 has a crucial role in tumor cell proliferation by its overexpression and highlight
its usefulness as a prognostic factor and potential therapeutic target in gastric cancer.
Gastric cancer is one of the most common causes of death from
cancer worldwide (Siegel et al, 2013). Recent advances in
diagnostic technologies and peri-operative management have
increased early detection of gastric cancer and decreased the
morbidity and mortality rates. However, patients with advanced
gastric cancer still frequently experience recurrence despite
extended radical resections, which results in an extremely poor
survival rate (Martin et al, 2002).
Numerous genes have been analysed to understand molecular
mechanisms of carcinogenesis and improve clinical outcomes for
human gastric cancers; however, only a few genes with frequent
alterations have been identified (Ushijima and Sasako, 2004) such
as gene amplifications of MET and ERBB2, hypermethylation of
p16 (Oue et al, 2002; Ding et al, 2003), mutations of TP53, APC
and E-cadherin (Becker et al, 1994; Maesawa et al, 1995; Lee et al,
2002), oncogenic activation of b-catenin and K-ras (Park et al, 1999)
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and inactivation of the mismatch repair gene hMLH1, which is
associated with microsatellite instability (Fang et al, 2003).
Including these reports, researchers have attempted to identify
biological factors involved in the malignancy of gastric cancer.
However, in clinical settings, only a few genes have been used as
diagnostic biomarkers and/or therapeutic targets (Bang et al, 2010).
We therefore wished to identify novel genes associated with the
progression of gastric cancer.
SET and MYND domain-containing protein 2 (SMYD2) (1q42)
was recently identified as a lysine methyltransferase for histone
H3K36, H3K4 and K370 of p53, K860 and K810 of Rb and K528 of
PARP1. It regulates transcription (Brown et al, 2006; Abu-Farha
et al, 2008), inhibits tumour suppressor proteins p53 (Huang et al,
2006) and Rb (Saddic et al, 2010; Cho et al, 2012), and enhances
the poly (ADP-ribose) activity of the oncogenic protein PARP1 in
cancer cells (Piao et al, 2014). Moreover, SMYD2 is a clinically
relevant prognostic marker for oesophageal squamous cell
carcinoma (ESCC), bladder carcinoma and paediatric acute
lymphoblastic leukaemia (Komatsu et al, 2009; Cho et al, 2012;
Sakamoto et al, 2014) and it could be used to predict a potentially
poor prognosis to plan more aggressive treatment for applicable
patients. However, to date, there has been no report on the clinical
and prognostic significance of SMYD2 in patients with primary
gastric cancer. These findings prompted us to investigate the effects
of SMYD2 overexpression and activation in primary gastric cancer.
Consequently, in this study, we demonstrated that SMYD2 was
frequently overexpressed in gastric cancer cell lines and primary
gastric cancers. Overexpression of SMYD2 was an indicator of
poor prognosis independent of other prognostic factors. We also
demonstrated that knockdown of SMYD2 suppressed cell pro-
liferation, migration and invasion in gastric cancer cell lines. Our
results provide evidence that SMYD2 could be an important
molecular marker to determine malignant properties and a target
for molecular therapy in patients with gastric cancer.
MATERIALS AND METHODS
Cell lines and primary tissue samples. A total of seven gastric
cancer cell lines (MKN7, MKN74, HGC27, MKN45, KatoIII,
NUGC4 and MKN28 cells) and a fibroblast cell line (WI-38) were
used in this study. HGC27 and WI-38 cells were cultured in
mixture of Dulbecco’s Minimum Essential Medium and F12
medium, and the other cell lines were cultured in RPMI-1640
medium. All culture media were purchased from Sigma (St. Louis,
MO, USA) and supplemented with 100ml l 1 foetal bovine serum
(Trace Scientific, Melbourne, VIC, Australia). All cell lines were
cultured in 5% carbon dioxide at 37 1C in a humidified chamber.
Primary tumour samples of gastric cancer were obtained from 147
gastric cancer patients, who underwent curative gastrectomy (R0)
at the Division of Digestive Surgery, Department of Surgery, Kyoto
Prefectural University of Medicine (Kyoto, Japan) between 2001
and 2003. These samples were embedded in paraffin after 24 h of
formalin fixation. Relevant clinical and survival data were available
for all patients. Written consent was always obtained in the formal
style and after approval by the local ethics committee. None of
these patients underwent endoscopic mucosal resection, palliative
resection, preoperative chemotherapy or radiotherapy, and none of
them had synchronous or metachronous multiple cancers in other
organs. Disease stage was defined in accordance with the
International Union against Cancer tumour-lymph node-metas-
tases classification (7th edition (Sobin and Wittekind, 2009)). The
median follow-up period for surviving patients was 54.5 months
(ranging from 0.5 to 84.2 months).
Quantitative real-time RT–PCR. Single-stranded complementary
DNA generated from total RNA was amplified with primers
specific for each gene, as described below. Abundance of messenger
RNA (mRNA) was measured with a quantitative real-time
fluorescence detection method (ABI StepOnePlus Sequence
Detection System; Applied Biosystems, Foster City, CA, USA)
using TaqMan Gene Expression Assays (Hs00220210_m1 for
SMYD2; Applied Biosystems) according to the manufacturer’s
instructions. Results of gene expression were calculated as a ratio
between SMYD2 and an internal reference gene (Hs99999903_m1
for b-actin; Applied Biosystems) that provides a normalisation
factor for the amount of RNA isolated from a specimen, and the
ratio was subsequently normalised by that of the control fibroblast
cell line (relative expression). This assay was performed in
duplicate for each sample.
Western blotting. Anti-SMYD2 rabbit polyclonal antibody was
generated against a 14-amino acid peptide from human SMYD2
(HPYISEIKQEIESH; Operon Biotechnology, Tokyo, Japan) and
purified through an affinity column. Anti-b-actin antibody was
purchased from Sigma, and anti-p53 (DO-7) and anti-p21
antibodies were from Novocastra Laboratories (Newcastle upon
Tyne, UK) and Santa Cruz Biotechnology (Santa Cruz, CA, USA),
respectively. Cells were lysed and their proteins were extracted
by M-PER Mammalian Protein Extraction Reagent (Thermo
Fisher Scientific, Waltham, MA, USA). Twenty micrograms of
proteins per lane were loaded for electrophoresis.
Knockdown of SMYD2 by siRNA and analysis of cell prolifera-
tion. We knocked down SMYD2 with small interfering RNA
(siRNA) targeting SMYD2 (SMARTpool #M-020291-00; Dharma-
con, Lafayette, CO, USA) and we used siRNA targeting luciferase
as a negative control (Luc, 50-CGUACGCGGAAUACUUCGA-30;
Sigma, Tokyo, Japan). Gastric cancer cell lines were transfected
with each siRNA (10 nmol l 1) with Lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Effects of SMYD2 knockdown on protein abundance
was confirmed by Western blotting. To measure cell proliferation,
the number of viable cells 24, 48 and 72 h after siRNA transfection
was assessed by the colorimetric water-soluble tetrazolium salt
assay (Cell counting kit-8; Dojindo Laboratories, Kumamoto,
Japan). Cell cycle was evaluated 72 h after transfection by
fluorescence-activated cell sorting (FACS) as described elsewhere
(Komatsu et al, 2009).
Transwell migration and invasion assays. Transwell migration
and invasion assays were carried out in 24-well modified Boyden
chambers (transwell-chamber, BD Transduction, Franklin Lakes,
NJ, USA). For invasion assays, the upper surfaces of the 6.4-mm
diameter filters with 8-mm pores that were used for migration
assays were precoated with Matrigel (BD Transduction). siRNA
transfectants (2 104 cells per well) were transferred into the
upper chamber. Following 48 h of incubation, migrated or invasive
cells on the lower surface of the filters were fixed and stained with
the Diff-Quik stain (Sysmex, Kobe, Japan), and stained cell nuclei
were counted directly in triplicate. We assessed the ability of the
cells to move through extracellular matrices by calculating the
number of cells, which is the ratio of the percentage invasion
through the matrigel-coated filters relative to migration through
the uncoated filters of test cells over that in the control cells as
described elsewhere (Kashimoto et al, 2012; Nishimura et al, 2013).
Immunohistochemistry. Primary tumour samples were fixed
with 10% formaldehyde in PBS, embedded in paraffin, sectioned
into 5-mm-thick slices and subjected to immunohistochemical
staining of SMYD2 with the avidin–biotin–peroxidase method as
described by Naoi et al (2008). In brief, after deparaffinization,
endogenous peroxidases were quenched by incubating the sections
for 20min in 3% H2O2. Antigen retrieval was performed by
heating the samples in 10mmol l 1 citrate buffer (pH 6.0) at 95 1C
for 60min. After treatment with Block Ace (Dainippon Sumitomo
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Pharmaceutical, Osaka, Japan) for 30min at room temperature,
sections were incubated at 4 1C overnight with the anti-SMYD2
(1 : 200) antibody. The avidin–biotin–peroxidase complex system
(Vectastain Elite ABC universal kit; Vector Laboratories Inc.,
Burlingame, CA, USA) was used for colour development with
diaminobenzidine tetrahydrochloride. Tissues were counterstained
with Mayer’s haematoxylin. To confirm the specificity of the anti-
SMYD2 antibody, a formalin-fixed oesophageal cancer cell line
overexpressing SMYD2 (KYSE170 cells), in which 450% of cells
showed staining of SMYD2 protein, was used as a positive control,
whereas KYSE170 cells incubated without the SMYD2 antibody
were used as a negative control (Supplementary Figure S1;
Komatsu et al, 2009). For scoring SMYD2 abundance, the intensity
(intensity score 0¼ negative, score 1¼weak, score 2¼moderate,
score 3¼ strong, as described below) and percentage of the
SMYD2-expressing cells in the total population (proportion score
0, o10%; score 1, 10 to 33%; score 2, 34 to 66%; score 3, 67 to
100%) were evaluated for each tumour sample using high-power
( 200) microscopy. In primary tumour samples, SMYD2 protein
was not detected in most of the non-tumorous gastric mucosa and
stroma. Primary tumours with no detectable SMYD2 (similar to
non-tumorous gastric mucosa and stroma) were given an intensity
score of 0, whereas those with the greatest SMYD2 abundance were
given an intensity score of 3. The remaining tumours were
categorised with intensity scores of 1 or 2 according to the intensity
of immunohistochemical staining for SMYD2. Finally, expression
of SMYD2 was graded based on the sum of the intensity score and
the proportion score: high expression (intensity plus proportion
scores X4) or low expression (intensity plus proportion scores
p3) (Tsuda, 2008).
Statistical analysis. Clinicopathological variables pertaining to the
corresponding patients were analysed for statistical significance by
the w2-test or Fisher’s exact test. For the analysis of survival,
Kaplan–Meier survival curves were constructed for groups based
on univariate predictors, and differences between the groups were
analysed with the log-rank test. Univariate and multivariate
survival analyses were performed using the likelihood ratio test
of the stratified Cox proportional hazards model. Differences
between subgroups were tested with the non-parametric Mann–
Whitney U-test. Differences were assessed with a two-sided test
and considered statistically significant at Po0.05.
RESULTS
Overexpression of SMYD2 in gastric cancer cell lines. Quanti-
tative RT–PCR and Western blotting analyses were performed to
test whether SMYD2 is overexpressed in gastric cancer cell lines
compared with the fibroblast cell line WI-38 (Figure 1A).
Expression of SMYD2 protein detected by the SMYD2-specific
antibody correlated with that of SMYD2 mRNA in gastric cancer
cell lines. SMYD2 was overexpressed in almost all gastric cancer
cell lines (five out of seven cell lines, 71.4%), suggesting this gene to
be a target for activation in gastric cancer cell lines (Figure 1A).
Because repression of p53 activity through SMYD2-mediated
methylation at K370 was reported previously (Huang et al, 2006),
we examined the status of TP53 mutation in the gastric cancer cell
lines by Western blotting. These statuses of TP53 mutation in
various cell lines are positively associated with their reported status
of TP53 mutation in the database (http://p53.free.fr/index.html)
(M¼mutant TP53; W¼wild-type TP53.). Although wild-type p53
is expected to be a more suitable substrate than mutant p53 for
SMYD2 (Huang et al, 2006; Komatsu et al, 2009), expression of
SMYD2 mRNA and protein was not correlated with the mutation
status and expression of p53 (Figure 1A).
Suppression of cell proliferation by knockdown of SMYD2. To
gain an insight into the potential role of SMYD2 as an oncogene
whose overexpression could be associated with gastric carcinogen-
esis, we first performed cell proliferation assays using siRNA
specific for SMYD2 and investigated whether knockdown of
SMYD2 would suppress proliferation of gastric cancer cell lines
that overexpress SMYD2. We chose the HGC27 cell line for these
assays, because it had the highest amount of SMYD2 protein


















































































































































































Figure 1. (A) Expression of SMYD2 mRNA (top) and protein (bottom) in seven gastric cancer cell lines compared with that in a fibroblast cell line
WI-38. Also, the status of TP53 mutation in each gastric cancer cell line was evaluated by Western blotting. The status of TP53 mutation was
positively associated with the reported status of TP53 mutation in the database (http://p53.free.fr/index.html, M¼mutant TP53; W¼wild-type
TP53. )**. (B) HGC27 cells were transfected with siRNA targeting SMYD2 or control luciferase (Luc) for the indicated times. Cell proliferation (top)
and SMYD2 protein expression (bottom) were compared between these cells. (C) Migration and invasion of HGC27 cells transfected with siRNA
targeting SMYD2. The graphs on the bottom show mean±s.d. (bars) of n¼4. The Mann–Whitney U-test was used for statistical analysis. Po0.05 is
considered statistically significant.
Overexpression of SMYD2 in gastric cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.543 359
efficiently knocked down 24–72 h after the transient introduction
of SMYD2-specific siRNA (siRNA-SMYD2) (Figure 1B) than with
the control luciferase siRNA (siRNA-Luc). We measured the
proliferation of these siRNA-transfected HGC27 cells. The
proliferation of the cells transfected with siRNA-SMYD2 was
51.6% lower than that of cells transfected with control siRNA
(siRNA-Luc) 72 h after transfection (Figure 1B).
Suppression of cell migration and invasion by knockdown of
SMYD2. Next, Transwell migration and invasion assays were
performed to examine the ability of HGC27 cells transfected with
siRNA-SMYD2 to move through pores under different conditions.
Uncoated membrane was used for migration assays, whereas
Matrigel-coated membrane was used for invasion assays. In
Figure 1C, the number of cells that migrated into the lower
chamber was significantly lower for siRNA-SMYD2-transfected
cells than for siRNA-Luc-transfected cells under both conditions,
suggesting that SMYD2 may increase the ability of gastric cancer
cells to migrate.
Correlation between suppression of cell proliferation by knock-
down of SMYD2 and TP53 mutation status. To gain further
insight into the potential association of SMYD2 with TP53
mutation status, we performed cell proliferation assays with the
NUGC4 cell line, which has wild-type TP53, and the MKN28 cell
line, which has mutant TP53. In both NUGC4 and MKN28 cell
lines, endogenous SMYD2 protein was efficiently knocked down
24–72 h after the transient introduction of SMYD2-specific siRNA
(Figure 2A and B, middle panels). An inhibitory effect of knockdown
of SMYD2 on cell proliferation was also observed in both cell lines
(Figure 2A and B. top panels), suggesting that this inhibitory effect is
not associated with TP53 mutation/expression status. Fluorescence-
activated cell sorting analysis demonstrated that transfection of both
NUGC4 and MKN28 cell lines with siRNA-SMYD2 resulted in an
accumulation of cells in the G0–G1 phase compared with
transfection with control siRNA. In addition, p21 protein abundance
was also increased at the protein level in siRNA-SMYD2-transfected
cells (Figure 2A and B, middle panels), suggesting that the
knockdown of SMYD2 directly or indirectly induced the produc-
tion of p21, which results mainly in G0–G1 arrest.
Immunohistochemical analysis of SMYD2 expression in pri-
mary gastric cancer. Because SMYD2 protein was overexpressed
in almost all gastric cancer cell lines, we hypothesised that SMYD2
would also be highly expressed in primary gastric cancer tissues
and would be involved in carcinogenesis and malignant outcomes.
We examined the clinicopathological significance of SMYD2 in
primary tumour samples based on the immunohistochemical
staining pattern of this protein. SMYD2 protein was observed in
both the cytoplasm and the nucleus of cancer cells regardless of
tumour differentiation (right and left panels, respectively, of
Supplementary Figure S2). We classified 147 gastric cancer samples
into positive or negative groups according to the intensity and
proportion scores of SMYD2 staining as described in the Materials
and Methods section. In primary tumours, SMYD2 protein was not
detected in most of the non-tumorous gastric mucosal cell
population (intensity score 0) (Figure 3A), and it was weakly
detected in the gastric fundic gland. Supplementary Table 1 shows
the distribution of patients based on the intensity and proportion
scores of SMYD2 immunoreactivity of tumour samples. A group of
high expression with the combined scores of 44 was considered
immunopositive and is shown in grey in this table. Kaplan–Meier
survival estimates showed that SMYD2 immunoreactivity in
tumour cells was statistically significantly associated with a worse
overall survival based on the intensity and proportion scores
(Figure 3C and D, respectively). Based on the combined scores,
patients in the high expression group had statistically significantly
poorer prognoses than did patients in the low expression group
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Figure 2. Effects of SMYD2 knockdown by siRNA (siRNA-SMYD2) compared with those of control siRNA (siRNA-Luc) in NUGC4 (wild-type TP53, A)
and MKN28 (mutant TP53, B) cell lines. Top: effects of knocking down endogenous SMYD2 on cell proliferation at the indicated times. Results are
mean±s.d. (bars) for quadruplicate experiments. The Mann–Whitney U-test was used for the statistical analysis: *Po0.05 vs siRNA-Luc-transfected
cells. Middle: effects of siRNA-SMYD2 on the abundance of endogenous SMYD2 and p21 proteins 24–72h after transfection of gastric cancer cell
lines. Bottom: representative results of the population in each phase of the cell cycle in gastric cancer cell lines assessed by FACS 72h after
treatment with siRNA.
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Correlation between SMYD2 protein abundance and clinico-
pathological characteristics in primary gastric cancer. The
association between SMYD2 protein abundance and clinicopatho-
logical characteristics is summarised in Table 1. SMYD2 protein
abundance was statistically significantly associated with larger
tumour size, higher incidence of lymphatic invasion and lymph
node metastasis, deeper invasion and higher recurrence rate, and
tended to be associated with higher incidence of venous invasion.
In the Cox proportional hazard regression model (Table 2),
univariate analyses demonstrated that SMYD2 protein abundance,
age, location, tumour size, venous and lymphatic invasion, pT
category and pN category were statistically significantly associated
with cause-specific survival. When data were stratified for multi-
variate analysis using both the forward and backward stepwise Cox
regression procedures, SMYD2 immunoreactivity in tumour cells
remained significant, with Po0.05 (hazard ratio, 4.26 (1.69–
10.72)) for overall survival in all patients, suggesting that SMYD2
immunoreactivity can be an independent predictor of overall
survival.
DISCUSSION
Lysine methyltransferases for histone or non-histone proteins have
emerged as attractive targets for disease treatments (Kelly et al,
2010), and intensive ongoing efforts have been made to clarify their
molecular mechanisms and clinical outcomes in cancers (Chang
and Hung, 2012; Anglin and Song, 2013; Shankar et al, 2013; Sarris
et al, 2014) and to develop novel drugs for this class of enzymes
(Wagner and Jung, 2012). The human SMYD family of lysine
methyltransferases is composed of five members (SMYD1–5)
(Brown et al, 2006), which have various roles in development and
cancer. Disruption of SMYD1 leads to perturbed cardiac
morphogenesis and embryonic lethality (Gottlieb et al, 2002).
SMYD3 is associated with cancer cell proliferation, and it is
overexpressed in hepatocellular, colorectal and breast carcinomas
(Hamamoto et al, 2004, 2006). SMYD4, as a potential tumour
suppressor, has a critical role in breast carcinogenesis at least partly
through inhibiting the expression of PDGFRA (Hu et al, 2009).
SMYD5, as a negative regulator of inflammatory response genes, is
recruited to a subset of TLR4-responsive promoters through its
association with NCoR corepressor complexes, where it trimethy-
lates histone H4 K20 (Stender et al, 2012).
SMYD2 methylates both histones (H2B, H3 and H4) and non-
histone proteins, including the tumour suppressor proteins, p53
and Rb, and the oncogenic protein, PARP1 (Brown et al, 2006;
Huang et al, 2006; Abu-Farha et al, 2008; Wu et al, 2011).
Methylation of K370 of p53 impairs its ability to bind to the
promoters of target genes (Chuikov et al, 2004; Huang et al, 2006).
Methylation of Rb at K860 generates an epitope that is selectively
recognised by the transcriptional repressor L3MBTL1, providing a
mechanism for recruiting L3MBTL1 to the promoters of specific
Rb/E2F target genes, thereby repressing their activities (Saddic
et al, 2010). In addition, SMYD2-dependent methylation of Rb at
K810 promotes cell cycle progression of cancer cells (Cho et al,
2012). Moreover, methylation of K528 on PARP1 enhances its
poly(ADP-ribose) activity in cancer cells (Piao et al, 2014). In
agreement with these observations, overexpression of SMYD2 is
associated with various human malignancies, such as ESCC
(Komatsu et al, 2009), bladder carcinoma (Cho et al, 2012) and
paediatric acute lymphoblastic leukaemia (Sakamoto et al, 2014),
indicating that SMYD2 acts as a cancer-promoting factor. More-
over, SMYD2 is involved in maintaining the self-renewal activity of
MLL-AF9-induced acute myeloid leukaemia (Abu-Farha et al,
2011) and might be related to the response to chemotherapy in
breast cancer (Barros Filho et al, 2010). These findings prompted
us to determine the clinicopathological and prognostic significance
of SMYD2 overexpression activation in primary gastric cancer.
Here, we hypothesised that overexpression/activation of SMYD2
may promote tumour cell proliferation and/or poor survival of
gastric cancer patients. To test this hypothesis, we examined the
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Figure 3. (A) Specific immunostaining of SMYD2 protein in a representative primary tumor sample. Based on this result, the intensity scores for
SMYD2 staining were determined as follows; 0¼ negative, 1¼weak, 2¼moderate, 3¼ strong). Scale bar: 20mm. (B–D) Cause-specific survival
rates of gastric cancer patients (as determined by Kaplan–Meier plots) depending on the scores of the intensity (C), proportion (D) and in
combination (B) based on the immunostaining analysis of their cancers. The log-rank test was used for statistical analysis. Po0.05 is considered
statistically significant.
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significance of its expression in cell lines and primary tumours of
gastric cancer. Consequently, we demonstrated that SMYD2 was
overexpressed in 38.1% (56/147) of primary gastric cancers as well
as in 71.4% (5/7) of gastric cancer cell lines and this overexpression
was an indicator of poor prognosis independent of other
prognostic factors. The intensity and proportion of SMYD2
abundance detected by immunohistochemical tissue staining was
correlated with the prognosis of gastric cancer patients. In
addition, knockdown of SMYD2 suppressed cell proliferation,
migration and invasion in the gastric cancer cell lines.
Because p53 and its target molecules, which regulate cell cycle
and trigger apoptosis after DNA damage, have a key role in a wide
range of human cancers, including gastric cancer (Caelles et al,
1994; Fenoglio-Preiser et al, 2003; Bellini et al, 2012), it is possible
that overexpression of SMYD2 promotes cell proliferation and/or
survival by inhibiting the transactivation activity of p53. Based on
this hypothesis, we performed siRNA-mediated knockdown of
SMYD2 which had an inhibitory effect on cell proliferation in
gastric cancer cells, which overexpress SMYD2, more or less
independently of TP53 mutation status. Cell cycle analysis by
FACS demonstrated that the inhibition of cell proliferation caused
by SMYD2 knockdown occurred mainly because of G0–G1 arrest.
This result was supported by our finding that increases in
expression of p21 protein were caused by SMYD2 knockdown,
although it remains unknown how SMYD2 inhibits the transcrip-
tion of p21 in a p53-independent manner. These results are
consistent with our previous findings of an inhibitory effect
on cell proliferation upon SMYD2 knockdown in TP53-mutant
ESCC cells and p53-null SaOS2 osteosarcoma cells (Komatsu
et al, 2009).
More recently, the first SMYD2 inhibitor AZ505 (AstraZeneca,
London, UK) was developed, which is highly selective and shows
an activity at submicromolar concentrations in vitro (Ferguson
et al, 2011). The IC50 of AZ505 for SMYD2 is 0.12 mM, which is
4600-fold greater than the IC50s of AZ505 for other histone
methyltransferases, such as SMYD3 (IC50483.3 mM), DOT1L
(IC50483.3 mM) and EZH2 (IC50483.3 mM), although functional
data on the consequences of chemical inhibition of SMYD2 have
not been reported (Ferguson et al, 2011). Moreover, anticancer
effects of similar lysine methyltransferase inhibitors have already
been proven in animals (Schenk et al, 2012; Willmann et al, 2012).
Overexpression of SMYD2 protein was detected in 38.1% of
patients with gastric cancer and 76.5% of patients with ESCC
(Komatsu et al, 2009). These findings suggest that the SMYD2
inhibitor AZ505 may be a key molecule for the treatment of
patients with these cancers. This drug is currently being evaluated
in vitro and vivo.
Table 1. Association between clinicopathologic







Total 147 56 91
Sex
Male 100 41 (73%) 59 (65%)
Female 47 15 (27%) 32 (35%) 0.2901
Age (years)
Mean 63 (range:27–89)
o60 56 23 (41%) 33 (36%)
X60 91 33 (59%) 58 (64%) 0.5036
Location
Upper 20 10 (18%) 10 (11%)
Middle 75 23 (41%) 52 (57%)
Lower 52 23 (41%) 29 (32%) 0.1505
Histopathological grading
Differentiated 73 32 (57%) 41 (45%)
Undifferentiated 74 24 (43%) 50 (55%) 0.1546
Tumor size (mm)
o40 84 26 (46%) 58 (64%)
X40 63 30 (54%) 33 (36%) 0.0394
Venous invasion
0 104 35 (63%) 69 (76%)
1–3 43 21 (38%) 22 (24%) 0.0846
Lymphatic invasion
0 80 20 (36%) 60 (66%)
1–3 67 36 (64%) 31 (34%) 0.0003
TNM classification
pT categories
pT1 83 24 (43%) 59 (65%)
pT2/3 34 16 (29%) 18 (20%)
pT4 30 16 (29%) 14 (15%) 0.0290
pN categories
N0 96 34 (61%) 62 (68%)
N1/2 28 7 (13%) 21 (23%)
N3 23 15 (27%) 8 (9%) 0.0204
pStage
I 94 31 (55%) 63 (69%)
II 16 6 (11%) 10 (11%)
III 37 19 (34%) 18 (20%) 0.2117
Rucurrence
Absent 117 39 (70%) 78 (86%)
Present 30 17 (30%) 13 (14%) 0.0188
Abbreviations: SMYD2¼ SET and MYND domain-containing protein 2; TNM¼ tumour-
lymph node-metastases. Statistically significant values are in bold.
aP-values are from w2- or Fisher’s exact test and were statistically significant at o0.05.
Table 2. Multivariate analysis using the stepwise Cox
regression procedures
Univariatea Multivariateb
Variables P-value HR 95% CI P-value
Sex
Male vs female 0.9583 2.749 1.134–6.665 0.0252
Age
X60 vs o60 0.0391 5.649 1.992–16.12 0.0011
Location






X40 vs o40 o0.0001 —
Venous invasion
Positive vs negative o0.0001 5.681 2.173–14.92 0.0004
Lymphatic invasion
Positive vs negative o0.0001 —
pT-stage
T3-4 vs T1-2 o0.0001 6.493 1.385–27.77 0.0177
pN-stage
N2-3 vs N0-1 o0.0001 17.54 4.672–66.66 o0.0001
SMYD2 expression
High vs low 0.0073 4.258 1.690–10.72 0.0021
Abbreviations: CI¼ confidence interval; HR¼hazard ratio; ML¼middle and lower;
SMYD2¼ SET and MYND domain-containing protein 2; U¼ upper. Statistically significant
values are in bold.
aKaplan–Meier method, and the statistical significance was determined by log-rank test.
bMultivariate survival analysis was performed using Cox’s proportional hazard model.
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In conclusion, this is the first report to show that SMYD2 has a
crucial oncogenic role and is a potential therapeutic target in
gastric cancer. We demonstrated the frequent overexpression of
SMYD2 protein and its prognostic value in patients with gastric
cancer. Although studies of larger cohorts are needed to validate
these findings before moving to clinical settings, our results
provide evidence that SMYD2 could be a pivotal molecular
marker to determine malignant properties of gastric cancer cells
and that it could be a target for molecular therapy in patients with
this cancer.
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